Carregant...
Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
Recently developed potent and selective CDK4/6 inhibitors fall into two classes based on structure and toxicity profiles in clinical studies. One class, exemplified by palbociclib and ribociclib, exhibits neutropenia as a dose-limiting toxicity and requires discontinuous dosing. In contrast, the str...
Guardat en:
| Publicat a: | Oncotarget |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Impact Journals LLC
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5546433/ https://ncbi.nlm.nih.gov/pubmed/28620137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18435 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|